ChangeBridge: Patent Grants - Biotech (C12N)

USPTO Patent Grant: CRISPR-Cas13 for SARS-CoV-2 Detection

The USPTO has granted patent US12577625B2 to The J. David Gladstone Institutes for a method using CRISPR-Cas13 enzyme to detect and quantify SARS-CoV-2 RNA. This technology aims to provide rapid, field-deployable diagnostics for SARS-CoV-2 infection, including variant identification.

USPTO Patent Grant: Selective Metal Recovery Agent and Method

The USPTO has granted patent US12577633B2 to Galdieria Co., Ltd. for an agent and method for selective metal recovery using materials derived from algae or porphyrins. The patent details a process involving adding the agent to a metal solution and then recovering the metal.

USPTO Patent Grant: Hexokinase 1b for Cancer Prognosis and Treatment

The USPTO has granted a patent (US12578339B2) for hexokinase 1 isoform B (HK1b) as a prognosis marker and treatment target for cancer. The patent was filed on July 19, 2020, and granted on March 17, 2026.

USPTO Patent Grant: Plasma piRNA Combination for Gastric Cancer Diagnosis

The USPTO has granted patent US12580080B2 to The First Affiliated Hospital of Wenzou Medical University for a plasma piRNA combination for the early diagnosis of gastric cancer. The patent describes a diagnostic model that uses piRNA expression profiles to predict gastric cancer risk with high accuracy.